


In re: Cantin et al.
Application No.: 10/537,630
Filed: June 3, 2005
Page 2

Amendments to the Claims

This listing of the claims will replace all prior versions and listings of the claims in the application:

1. (Currently Amended) A compound of Formula (I)



(I)

wherein


R¹ and R² are independently H, C₁-C₆ alkyl, or C₃-C₆ cycloalkyl;

L is a linker and selected from the group consisting of:

-(CH₂)_m-X-,

-Y-(CH₂)_n-X-,

and



wherein

X is selected from the group consisting of O, S, S(=O), and S(=O)₂, wherein L

can be

Y is selected from the group consisting of O, NR⁵, S, S(=O), and S(=O)₂,
m is 1, 2, or 3,
n is 2, 3, or 4,
t is 0 or 1,

p is 0,1, 2, or 3,

q is 1, 2, 3, or 4,

wherein the sum of p and q is 1, 2, 3, or 4;

Ar is selected from the group consisting of phenyl and a 6-membered heteroaryl ring containing up to three N atoms, said Ar being optionally substituted at any available position by 1 to 5 independently selected R³ groups, and
optionally fused to a 5- or 6-membered saturated carbocyclic ring,
a 5- or 6-membered unsaturated carbocyclic ring, or
a 5- or 6-membered heterocyclic ring containing up to 3 additional heteroatoms selected from the group consisting of N, O, and S,
wherein
said fused ring may be optionally substituted at any available position by 1 to 4 independently selected R⁴ groups;

R³ is selected from the group consisting of:

- hydroxy,
- SH,
- halo,
- CN,
- NO₂,
- C(=O)OH,
- C(=O)-OC₁-C₆ alkyl,
- C(=O)-OC₃-C₆ cycloalkyl,
- NR⁶R⁷,
- C(=O)NR⁶R⁷,
- C(=S)NR⁶R⁷,
- C₁-C₆ alkyl optionally substituted with halo, OH, NR⁶R⁷, or C₁-C₆ alkoxy,
- C₁-C₆ haloalkyl,
- C₁-C₆ alkoxy,
- C₁-C₆ thioalkyl,

In re: Cantin et al.
Application No.: 10/537,630
Filed: June 3, 2005
Page 4

- C₂-C₆ alkenyl,
 - C₁-C₆ haloalkoxy,
 - C₃-C₈ cycloalkyl,
 - C₃-C₈ cycloalkoxy,
 - phenoxy optionally substituted on the phenyl ring with halo, C₁-C₆ alkyl, or C₁-C₆ alkoxy, and
 - a mono or bicyclic ring radical selected from the group consisting of
 - a) phenyl optionally fused to
 - a 5- or 6-membered saturated or partially unsaturated carbocyclic ring, or
 - a 5- or 6-membered saturated or partially unsaturated heterocyclic ring containing from 1-3 heteroatoms selected from the group consisting of N, O, and S,
 - b) a 5- or 6-membered heterocyclic ring radical containing up to 4 heteroatoms selected from N, O, or S, optionally fused to
 - a 5- or 6-membered saturated or partially unsaturated carbocyclic ring, or
 - a 5- or 6-membered saturated or partially unsaturated heterocyclic ring containing from 1-3 heteroatoms selected from the group consisting of N, O, and S,
- said mono or bicyclic ring radical being optionally substituted with up to 5 groups independently selected from the group consisting of
- halo,
 - hydroxy,
 - oxo,
 - CN,
 - C₁-C₆ alkyl optionally substituted with halo, OH, NR⁶R⁷, or C₁-C₆ alkoxy,
 - C₁-C₆ haloalkyl,

In re: Cantin et al.
Application No.: 10/537,630
Filed: June 3, 2005
Page 5

- C₁-C₆ alkoxy,
- C₁-C₆ thioalkyl,
- C₁-C₆ haloalkoxy,
- C₃-C₈ cycloalkyl,
- C₃-C₈ cycloalkoxy,
- C₁-C₆ acyl,
- C(=O)OH,
- CH₂C(=O)OH,
- NR⁶R⁷,
- C(=O)NR⁶R⁷,
- C(=O)OC₁-C₆ alkyl, and
- C(=O)OC₃-C₆ cycloalkyl;

R⁴ is selected from the group consisting of:

- Oxo,
- hydroxy,
- halo,
- CN,
- NR⁶R⁷,
- C₁-C₆ alkyl optionally substituted with OH, NR⁶R⁷, or C₁-C₆ alkoxy,
- C₁-C₆ haloalkyl,
- C₁-C₆ alkoxy,
- C₁-C₆ thioalkyl,
- C₁-C₆ haloalkoxy,
- C₃-C₈ cycloalkyl, and
- C₃-C₈ cycloalkoxy;

R⁵ is selected from the group consisting of:

- H,

In re: Cantin et al.
Application No.: 10/537,630
Filed: June 3, 2005
Page 6

- C₁-C₆ alkyl optionally substituted with C₃-C₆ cycloalkyl,
- C₁-C₆ acyl,
- benzyl optionally substituted with halo, C₁-C₆ alkoxy, (C₁-C₆) alkyl, CN, NH₂, N[(C₁-C₃)alkyl]₂, NO₂, or CF₃,
- C₃-C₆ cycloalkyl, and
- C(=O)OC₁-C₆ alkyl;

R⁶ and R⁷ are independently selected from the group consisting of:

- H,
- C₁-C₆ alkyl optionally substituted with C₃-C₆ cycloalkyl,
- C₁-C₆ acyl,
- benzyl optionally substituted with halo, C₁-C₆ alkoxy, (C₁-C₆) alkyl, CN, NH₂, N[(C₁-C₃)alkyl]₂, NO₂, or CF₃,
- C₃-C₆ cycloalkyl, and
- phenyl optionally substituted with halo, C₁-C₆ alkoxy, (C₁-C₆) alkyl, CN, N[(C₁-C₃)alkyl]₂, NO₂, or CF₃,

or

R⁶ and R⁷ may be taken together with the nitrogen atom to which they are attached to form a 5- or 6-membered heterocyclic ring optionally interrupted by NR⁵ or O; and pharmacologically acceptable esters and salts thereof.

2. (Canceled)

3. (Currently Amended) The compound of claim 1, wherein R¹ and R² are independently H or C₁-C₆ alkyl; L is a linker and selected from the group consisting of:

-(CH₂)_m-X-, and

-Y-(CH₂)_n-X-,

wherein

X is selected from the group consisting of O, S, S(=O), and S(=O)₂,

Y is selected from the group consisting of O, NR⁵, S, S(=O), and

S(=O)₂,

m is 1, 2, or 3,

n is 2, 3, or 4;

Ar is a 6-membered heteroaryl ring containing up to three N atoms, optionally substituted at any available position by 1 to 5 independently selected R³ groups, and optionally fused to a 5- or 6-membered saturated carbocyclic ring,

a 5- or 6-membered unsaturated carbocyclic ring, or

a 5- or 6-membered heterocyclic ring containing up to 3

additional heteroatoms selected from the group consisting of N,

O, and S,

wherein

said fused ring may be optionally substituted at any available position by 1 to 4 independently selected R⁴ groups;

and

m, n, R³, R⁴, R⁵, R⁶, and R⁷ are as defined in claim 1.

4. (Original) The compound of claim 1, wherein

R¹ and R² are independently H or C₁-C₆ alkyl;

L is -Y-(CH₂)_n-X-,

wherein

X is O,

Y is O;

Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R³ groups;

and

n, R³, R⁶, and R⁷ are as defined in claim 1.

In re: Cantin et al.
Application No.: 10/537,630
Filed: June 3, 2005
Page 8

5. (Original) The compound of claim 1, wherein
 R^1 and R^2 are independently H or C₁-C₆ alkyl;
L is -Y-(CH₂)_n-X-,
wherein

X is O,

Y is O;

Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R^3 groups,
and
fused to a 5- or 6-membered saturated carbocyclic ring, a 5- or 6-membered unsaturated carbocyclic ring, or a 5- or 6-membered heterocyclic ring containing up to 3 additional heteroatoms selected from N, O, and S,

wherein

said fused ring may be optionally substituted at any available position by 1 to 4 independently selected R^4 groups;

and

n, R^3 , R^4 , R^6 , and R^7 are as defined in claim 1.

6. (Original) The compound of claim 1, wherein
 R^1 and R^2 are independently H or C₁-C₆ alkyl;
L is -Y-(CH₂)_n-X-,
wherein

X is O,

Y is NR⁵;

Ar is a 6-membered heteroaryl ring containing up to three N atoms, optionally substituted at any available position by 1 to 5 independently selected R^3 groups; and

n, R^3 , R^5 , R^6 , and R^7 are as defined in claim 1.

7. (Canceled)

8. (Original) The compound of claim 1, wherein
R¹ and R² are independently H or C₁-C₆ alkyl;
L is -(CH₂)_m-X-,
wherein
X is O;
Ar is a 6-membered heteroaryl ring containing up to three N atoms, optionally substituted at any available position by 1 to 5 independently selected R³ groups,
and
optionally fused to a 5- or 6-membered saturated carbocyclic ring,
a 5- or 6-membered unsaturated carbocyclic ring, or
a 5- or 6-membered heterocyclic ring containing up to 3 additional heteroatoms selected from N, O, and S,
wherein
said fused ring may be optionally substituted at any available position by 1 to 4 independently selected R⁴ groups;

and

m, R³, R⁴, R⁶, and R⁷ are as defined in claim 1

9. (Currently Amended) A compound selected from the group consisting of:
((1S)-5-{2-[(3-methyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]ethoxy}-2,3-dihydro-1H-inden-1-yl)acetic acid;
2-((1S)-5-{2-[6-(4-acetylphenyl)(2-pyridyl)]ethoxy}indanyl)acetic acid;
2-{(1S)-5-[3-(3,7-dimethylbenzo[d]isoxazol-6-yloxy)propoxy]indanyl}acetic acid;
2-{(1S)-5-[3-(3-methyl-7-propylbenzo[d]isoxazol-6yloxy)propoxy]indanyl}acetic acid;

In re: Cantin et al.
Application No.: 10/537,630
Filed: June 3, 2005
Page 10

2-{5-[2-(6-(2H-benzo[3,4-d]1,3-dioxolan-5-yl)(2-pyridyl))ethoxy](1S)indanyl}
(2S)butanoic acid;

(2S)-2-((1S)-5-{2-[6-(4-ethylphenyl)(2-pyridyl)]ethoxy}indanyl)butanoic acid;

2-[(1S)-5-(3-{[2-(4-ethylphenyl)-5-methylpyrimidin-4-yl]methylamino}propoxy)
indanyl]acetic acid;

2-((1S)-5-{3-[(2-(2H-benzo[3,4-d]1,3-dioxolen-5-yl)-5-methylpyrimidin-4-yl)
methylamino]propoxy}indanyl)acetic acid;

2-[(1S)-5-(3-{2-methyl-4-[3-(trifluoromethyl)(1,2,4-thiadiazol-5-yl)]phenoxy}
propoxy)indanyl]acetic acid;

2-{(1S)-5-[3-({2-[4-(tert-butyl)phenyl]-5-methylpyrimidin-4-yl}methylamino)
propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[2-propyl-4-(trifluoromethyl)phenoxy]propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(methyl{5-methyl-2-[4-(methylethyl)phenyl]pyrimidin-4-yl}amino)
propoxy]indanyl}acetic acid;

2-[(1S)-5-(3-{[2-(4-ethoxyphenyl)-5-methylpyrimidin-4-yl]methylamino}
propoxy)indanyl]acetic acid;

2-[(1S)-5-(3-{[2-(4-ethoxyphenyl)-5-methylpyrimidin-4-yl]methylamino}
propoxy)indanyl]acetic acid;

2-[(1S)-5-(3-{[5-fluoro-2-(4-methoxyphenyl)pyrimidin-4-yl]methylamino}
propoxy)indanyl]acetic acid;

2-{(1S)-5-[3-({5-fluoro-2-[4-(methylethyl)phenyl]pyrimidin-4-yl}methylamino)
propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[(2-(2H-benzo[3,4-d]1,3-dioxolan-5-yl)-5-fluoropyrimidin-4-yl)
methylamino]propoxy}indanyl)acetic acid;

((1S)-5-{3-[4-(4-ethyl-1,3-thiazol-2-yl)-2-propylphenoxy]propoxy}-2,3-dihydro-

In re: Cantin et al.
Application No.: 10/537,630
Filed: June 3, 2005
Page 11

1H-inden-1-yl)acetic acid;

2-((1S)-5-{3-[4-(5-acetyl-4-methyl(1,3-thiazol-2-yl))-2-propylphenoxy]propoxy}indanyl)acetic acid;

2-[(1S)-5-(3-{4-[4-(tert-butyl)(1,3-thiazol-2-yl)]-2-propylphenoxy}propoxy)indanyl]acetic acid;

2-(4-{3-[(1S)-1-(carboxymethyl)indan-5-yloxy]propoxy}-3-propylphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid;

2-[(1S)-5-(3-{2-propyl-4-[4-(trifluoromethyl)(1,3-thiazol-2-yl)]phenoxy}propoxy)indanyl]acetic acid;

2-[(1S)-5-[3-(2-propyl-4-(4,5,6-trihydrocyclopenta[1,2-d]1,3-thiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-(4-{3-[(1S)-1-(carboxymethyl)indan-5-yloxy]propoxy}phenyl)-4-methyl-1,3-thiazole-5-carboxylic acid;

2-((1S)-5-{3-[4-(4,5-dimethyl(1,3-thiazol-2-yl))phenoxy]propoxy}indanyl)acetic acid;

2-((1S)-5-{3-[4-(4-methoxy(1,3-thiazol-2-yl))phenoxy]propoxy}indanyl)acetic acid;

2-[(1S)-5-[3-(4-(4,5,6,7-tetrahydrobenzothiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[4-(4-ethoxy(1,3-thiazol-2-yl))-2-propylphenoxy]propoxy}indanyl)acetic acid;

2-[(1S)-5-[3-(2-propyl-4-(4,5,6,7-tetrahydrobenzothiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[4-(4-ethoxy(1,3-thiazol-2-yl))-2-methoxyphenoxy]propoxy}indanyl)acetic acid;

2-((1S)-5-{3-[4-(4,5-dimethyl(1,3-thiazol-2-yl))-2-methoxyphenoxy]propoxy}indanyl)acetic acid;

2-[(1S)-5-[3-(2-methoxy-4-(4,5,6-trihydrocyclopenta[1,2-d]1,3-thiazol-2-yl)

In re: Cantin et al.
Application No.: 10/537,630
Filed: June 3, 2005
Page 12

phenoxy)propoxy]indanyl}acetic acid;

2-[(1S)-5-(3-{2-methoxy-4-[4-(methylethoxy)(1,3-thiazol-2-yl)]phenoxy}
propoxy)indanyl]acetic acid;

[(1S)-5-(3-{[5-(4,5-dimethyl-1,3-thiazol-2-yl)-2-pyridinyl]oxy}propoxy)-2,3-dihydro-
1H-inden-1-yl]acetic acid;

2-((1S)-5-{3-[4-(4-ethyl(1,3-thiazol-2-yl))-2-methoxyphenoxy]propoxy} indanyl)acetic
acid;

2-{(1S)-5-[3-(2-methoxy-4-(4,5,6,7-tetrahydrobenzothiazol-2-yl)
phenoxy)propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[4-(5-acetyl-4-methyl(1,3-thiazol-2-yl))-2-methoxyphenoxy]
propoxy}indanyl)acetic acid;

2-((1S)-5-{3-[5-(5-acetyl-4-methyl(1,3-thiazol-2-yl))(2-pyridyloxy)]
propoxy}indanyl)acetic acid;

2-((1S)-5-{3-[5-(4-ethyl(1,3-thiazol-2-yl))(2-pyridyloxy)]propoxy}indanyl)acetic acid;
2-{(1S)-5-[3-(4-(4,5,6,7-tetrahydrobenzoxazol-2-yl)phenoxy)propoxy] indanyl}acetic
acid;

2-((1S)-5-{3-[2-methoxy-4-(4-methoxy(1,3-thiazol-2-yl))phenoxy]
propoxy}indanyl)acetic acid;

2-[(1S)-5-(3-{[2-(4-fluorophenyl)-6-methylpyrimidin-4-yl]methylamino}
propoxy)indanyl]acetic acid;

2-[2-(4-{3-[(1S)-1-(carboxymethyl)indan-5-yloxy]propoxy}-3-propylphenyl)-1,3-
thiazol-4-yl]acetic acid;

2-((1S)-5-{3-[4-(4-ethoxy-5-methyl(1,3-thiazol-2-yl))-2-propylphenoxy]
propoxy}indanyl)acetic acid;

2-[(1S)-5-(3-{4-[5-(N,N-dimethylcarbamoyl)-4-methyl(1,3-thiazol-2-yl)]-2-

In re: Cantin et al.
Application No.: 10/537,630
Filed: June 3, 2005
Page 13

propylphenoxy}propoxy]indanyl]acetic acid;

2-{(1S)-5-[3-(2-propyl-4-(5,6,7-trihydro-2H-pyrano[2,3-d]1,3-thiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-[(1S)-5-(3-{[2-(4-cyclohexylphenyl)-6-methylpyrimidin-4-yl]methylamino} propoxy)indanyl]acetic acid;

2-{(1S)-5-[3-(2-methoxy-4-(4,5,6,7-tetrahydrobenzoxazol-2-yl)phenoxy) propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[4-(4-ethyl(1,3-oxazol-2-yl))-2-propylphenoxy]propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(2-propyl-4-(4,5,6,7-tetrahydrobenzoxazol-2-yl)phenoxy) propoxy]indanyl}acetic acid;

2-[(1S)-5-(3-{4-[4-(methylethoxy)(1,3-thiazol-2-yl)]-2-propylphenoxy} propoxy)indanyl]acetic acid;

2-{(1S)-5-[3-(2-propyl-4-(1,3-thiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[4-(5-acetyl-4-methyl(1,3-oxazol-2-yl))-2-propylphenoxy] propoxy}indanyl)acetic acid;

2-((1S)-5-{3-[4-(4-ethyl(1,3-oxazol-2-yl))-2-methoxyphenoxy]propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(2-methoxy-4-(1,3-thiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[4-(4-ethoxy-5-methyl(1,3-thiazol-2-yl))-2-methoxyphenoxy] propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(2-methoxy-4-(5,6,7-trihydro-2H-pyrano[2,3-d]1,3-thiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-{(1S)-5-[3-(4-phenoxy-2-propylphenoxy)propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[4-(5,5-dimethyl-7-oxo(4,5,6-trihydrobenzothiazol-2-yl))-2-

In re: Cantin et al.
Application No.: 10/537,630
Filed: June 3, 2005
Page 14

propylphenoxy]propoxy}indanyl)acetic acid;
2-{(1S)-5-[3-(4-benzothiazol-2-yl-2-methoxyphenoxy)propoxy]indanyl}acetic acid;
2-{(1S)-5-[3-(2-ethoxy-4-(4,5,6,7-tetrahydrobenzothiazol-2-yl)phenoxy)
propoxy]indanyl}acetic acid;
2-{(1S)-5-[3-(2-propoxy-4-(4,5,6,7-tetrahydrobenzothiazol-2-yl)phenoxy)
propoxy]indanyl}acetic acid;
2-{(1R)-5-[3-(2-propyl-4-(5,6,7-trihydro-2H-pyrano[2,3-d]1,3-thiazol-2-yl)
phenoxy)propoxy]indanyl}acetic acid; and
[(1S)-5-((3-[4-(6,7-dihydro-5H-pyrano[3,2-d][1,3]thiazol-2-yl)-2-
propylphenoxy]propyl)sulfanyl)-2,3-dihydro-1H-inden-1-yl]acetic acid.
or a pharmaceutically acceptable salt thereof.

10. (Original) A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of claim 1 in combination with a pharmaceutically acceptable carrier.

11. (Original) A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of claim 1, in combination with a pharmaceutically acceptable carrier and one or more pharmaceutical agents.

12. (Original) The pharmaceutical composition of claim 11, wherein said pharmaceutical agent is selected from the group consisting of PPAR agonists, sulfonylurea drugs, non-sulfonylurea secretagogues, α -glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose output lowering compounds, insulin, anti-obesity agents, HMG CoA reductase inhibitors, nicotinic acid, bile acid sequestrants, fibric acid derivatives, and anti-hypertensive agents.

13. (Original) A composition comprising an effective amount of one or more compounds of claim 1 in combination with an inert carrier.

14. (Withdrawn)(Currently Amended) A method of treating diabetes comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1, wherein said diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes adult, and gestational diabetes.

15. (Canceled)

16. (Withdrawn) A method of treating Syndrome X comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

17. (Withdrawn)(Currently Amended) A method of treating diabetes-related disorders comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1, wherein said diabetes-related disorder is selected from the group consisting of hyperglycemia, hyperinsulinemia, impaired glucose tolerance, impaired fasting glucose, dyslipidemia, hypertriglyceridemia, and insulin resistance.

18. (Canceled)

19. (Withdrawn) A method of treating obesity comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

20. (Withdrawn)(Currently Amended) A method of treating cardiovascular diseases comprising the step of administering to a subject in need thereof a therapeutically

In re: Cantin et al.
Application No.: 10/537,630
Filed: June 3, 2005
Page 16

effective amount of a compound of claim 1, wherein said cardiovascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, coronary artery disease and hypertension.

21. (Withdrawn)(Currently Amended) A method of treating diabetes comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 in combination with one or more pharmaceutical agents, wherein said diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes adult, and gestational diabetes.

22. (Withdrawn) The method of claim 21, wherein said pharmaceutical agent is selected from the group consisting of PPAR agonists, sulfonylurea drugs, non-sulfonylurea secretagogues, α -glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose output lowering compounds, insulin, and anti-obesity agents.

23. (Canceled)

24. (Withdrawn) A method of treating Syndrome X comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 in combination with one or more pharmaceutical agents.

25. (Withdrawn) The method of claim 24, wherein said pharmaceutical agent is selected from the group consisting of PPAR agonists, sulfonylurea drugs, non-sulfonylurea secretagogues, α -glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose output lowering compounds, insulin, and anti-obesity agents.

26. (Withdrawn)(Currently Amended) A method of treating diabetes-related disorders comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 in combination with one or more pharmaceutical

agents, wherein said diabetes-related disorder is selected from the group consisting of hyperglycemia, hyperinsulinemia, impaired glucose tolerance, impaired fasting glucose, dyslipidemia, hypertriglyceridemia, and insulin resistance.

27. (Canceled)

28. (Withdrawn) The method of claim 27, wherein said pharmaceutical agent is selected from the group consisting of PPAR agonists, sulfonylurea drugs, non-sulfonylurea secretagogues, α -glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose output lowering compounds, insulin, and anti-obesity agents.

29. (Withdrawn)(Currently Amended) A method of treating diabetes, Syndrome X, or diabetes-related disorders comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 in combination with one or more agents selected from the group consisting of HMG CoA reductase inhibitors, nicotinic acid, bile acid sequestrants, fibric acid derivatives, and anti-hypertensive agents, wherein said diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes adult, and gestational diabetes, and said diabetes-related disorder is selected from the group consisting of hyperglycemia, hyperinsulinemia, impaired glucose tolerance, impaired fasting glucose, dyslipidemia, hypertriglyceridemia, and insulin resistance.

30. (Canceled)

31. (Withdrawn) The method of any one of claims 21 to 30, wherein the compound of claim 1 and one or more pharmaceutical agents are administered as a single pharmaceutical dosage formulation.

32-35. (Canceled)

36. (Withdrawn) A method of stimulating insulin secretion in a subject in need thereof by administering to said subject a compound of claim 1.


37. (Withdrawn)(Currently Amended) Compounds according to claim 1 for the treatment and/or prophylaxis of diabetes and diabetes-related disorders, wherein said diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes adult, and gestational diabetes, and said diabetes-related disorder is selected from the group consisting of hyperglycemia, hyperinsulinemia, impaired glucose tolerance, impaired fasting glucose, dyslipidemia, hypertriglyceridemia, and insulin resistance.

38. (Original) Medicaments containing at least one or more compounds according to claim 1 in combination with at least one pharmaceutically acceptable, pharmaceutically safe carrier or excipient.

39. (Canceled)

40. (Currently Amended) Medicaments according to claim 38 for the treatment and/or prophylaxis of diabetes, wherein said diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes adult, and gestational diabetes.

41. (New) A compound having the structure of



, or a pharmaceutically acceptable salt thereof.

42. (New) A method of treating diabetes comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 41, wherein said diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes adult, and gestational diabetes.

43. (New) A method of treating Syndrome X comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 41.

44. (New) A method of treating diabetes-related disorders comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 41, wherein said diabetes-related disorder is selected from the group consisting of hyperglycemia, hyperinsulinemia, impaired glucose tolerance, impaired fasting glucose, dyslipidemia, hypertriglyceridemia, and insulin resistance.

45. (New) A method of treating obesity comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 41.

46. (New) A method of treating cardiovascular diseases comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 41, wherein said cardiovascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, coronary artery disease and hypertension.